Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistan…
$1.03+0.98%
报价 2026-11-06
市值
$60M
EV
$30M
PE (TTM)
9.7x
预期 PE (FY2026)
1.5x
52 周区间距高点 -65.4%
$1.02$2.98
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| SPROSpero Therapeutics, Inc. | $60M | +1.0% | -96.9% | 100% | 9.7x | 3.9x | 4.0x | |
| IRDOpus Genetics, Inc. | $347.8M | +4.4% | -1.5% | 99.9% | – | – | – | |
| HURATuHURA Biosciences, Inc. | $103.9M | +1.2% | +50.0% | 0% | – | – | – | |
| SEERSeer, Inc. | $90.3M | -4.1% | -4.1% | 47% | – | – | – | |
| INOInovio Pharmaceuticals, Inc. | $83.9M | -16.2% | +10800.0% | 0% | – | – | – | |
| CGTXCognition Therapeutics, Inc. | $65.3M | +8.1% | +14.4% | 0% | – | – | – | |
| CRBPCorbus Pharmaceuticals Holdings, Inc. | $59.4M | +7.3% | 0.0% | 0% | – | – | – | |
| MCRBSeres Therapeutics, Inc. | $19.7M | -5.3% | +133.3% | -20.9% | – | – | – | |
| ABOSAcumen Pharmaceuticals, Inc. | $16.2M | +4.5% | -100.0% | 0% | – | – | – | |
| 同行中位数 | – | – | +7.2% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。
研究材料
电话会纪要摘要
暂无纪要摘要。